MedTrace Logo

SC2i VIPER: EnVenomation Investigation Pilot to Evaluate Recovery

NCT03170297 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2025-08-12

No results posted yet for this study

Summary

The purpose of this study is to pilot data for a systematic molecular characterization of pathophysiologic perturbations incurred by snake envenomation and compare this to other inflammatory physiologic states such as trauma and sepsis. This sub-study will analyze samples of participants enrolled under the parent study "Surgical Critical Care Initiative Tissue and Data Acquisition Protocol".

Conditions

  • Critical Illness

Interventions

OTHER

Research interventions of blood sampling and data collection

Patient-Specific Functional Scale (PSFS) survey will be administered to patients to record symptoms at both the time of evaluation in the emergency department and in follow up by phone at 3, 7, 14, 21 and 28 days after discharge from the emergency department or hospital. The rest of the patients' care will be as usual care, and patients will have had research interventions of blood sampling and data collection as noted in the previously approved SC2i Tissue Data Acquisition Protocol (TDAP) Pro00054947 (ClinicalTrial.gov ID: NCT02182180).

Sponsors & Collaborators

  • Uniformed Services University of the Health Sciences

    collaborator FED

  • United States Department of Defense

    collaborator FED

  • Duke University

    collaborator OTHER

  • Emory University

    collaborator OTHER

  • Grady Health System

    collaborator OTHER

  • Walter Reed National Military Medical Center

    collaborator FED

  • Henry M. Jackson Foundation for the Advancement of Military Medicine

    lead OTHER

Principal Investigators

  • Eric A Elster, MD · Uniformed Services University of the Health Sciences

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-05
Primary Completion
2019-12-15
Completion
2019-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03170297 on ClinicalTrials.gov